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Abstract Meta-iodbenzylguanidine scintigraphy (MIBG
scintigraphy) shows reduced uptake in idiopathic Parkinson’s
disease (IPD), idiopathic REM sleep behavior disorder (IRBD)
and Lewy body dementia (LBD), but not in other parkinsonian
or dementia syndromes. We retrospectively reevaluated 50
patients. Concordance rate between last clinical diagnosis and
scintigraphy diagnosis was only given in two-thirds of the
patients. Confounding factors were: decreasing heart/medias-
tinum ratio (HMR) with progressive age, higher HMR in
women and possibly interference with antihypertensive medi-
cation. Standardization of the methods and precise clinical
guidelines are warranted for better clinical use.
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Introduction
Meta-iodbenzylguanidine scintigraphy (MIBG scintigra-
phy) shows reduced postsynaptic noradrenergic cardiac
uptake in idiopathic Parkinson’s disease (IPD), idiopathic
REM sleep behavior disorder (IRBD) and Lewy body
dementia (LBD) [1, 2]. This probably reflects cardiac
sympathetic denervation due to degeneration of postgan-
glionic sympathetic fibers [3, 4]. In contrast, the cardiac
uptake is normal in parkinsonian syndromes due to tauop-
athy and other dementia syndromes [5–8]. Notably, this
diagnostic tool is easily applicable, the radioactive com-
pound rather cheap in comparison to other ligands and the
patients do not need to withdraw from the current antipar-
kinsonian medications. Therefore, it has been proposed as a
diagnostic tool for differentiation of parkinsonian and
dementia syndromes at the early stages [9–11]. Despite
these promising characteristics, usefulness of routine
application outside selected research cohorts has not yet
been proven. Therefore, the purpose of the present study
was to evaluate the diagnostic utility of MIBG scintigraphy,
when performed in unselected patients at an early stage of a
parkinsonian or dementia syndrome, by comparison of the
MIBG diagnosis with the last clinical diagnosis.
Subjects
Fifty consecutive patients with different parkinsonian or
dementia syndromes were included in this study. There
were 26 women and 24 men. The age was 65 ± 35 years
and the range 38–87 years. Notably, parkinsonism started
at an early age (39 years) in one patient. However, genetic
analyses were not performed.
Methods
All patients underwent MIBG scintigraphy at an early
clinical stage of their disease. We compared concordance of
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MIBG diagnosis (MD) with the best available clinical
diagnosis (CD), in conformity with the current diagnostic
criteria [12–16] and mean CD at the last follow-up visit. The
total mean follow-up time (first to last visit) of the patients
was 2.7 ± 7 years. The MIBG diagnosis was based on the
delayed heart/mediastinum uptake ratio (HMR) taken 4 h
after injection of the analogon [11]. A unique cutoff of 1.6
was chosen with lower values defined as abnormal. This
cutoff was based on the available results of other studies
with well-defined control groups [17] and on the labora-
tory’s control group of non-parkinsonian patients who had
had an MIBG scintigraphy for other reasons, mostly exclu-
sion of phaeochromocytoma. It was further supported by
literature [5, 11, 17]. The clinical diagnosis was based on
established diagnostic criteria [17–19]. The control group
included nine subjects: four women and five men, with a
mean age of 42 ± 19 years. The concordance of MD and
CD was analyzed in the following three clinical setups:
1. Setup A (39 patients): differentiation between IPD and
other parkinsonian syndromes (PS) or essential tremor
(eT).
2. Setup B (9 patients): differentiation between LBD and
other dementia syndromes.
3. Setup C (2 patients): prognostic evaluation of iRBD.
All patients were maintained on their antiparkinsonian or
antihypertensive medications (13 patients). Nine patients in
setup A received antihypertensive medication, four patients
in setup B (two patients received calcium antagonists, one
patient had angiotensine convertase enzyme (ACE) inhibi-
tor and one patient amiodaron) and none in setup C. Based
on published recommendations [17], we screened the charts
also for other types of medication, possibly interfering with
MIBG scintigraphy. These medications, namely tricyclic
antidepressants, serotonin reuptake inhibitors and calcium
antagonists are listed in Table 1.
All data were made anonymous and retrospectively
analyzed. The study was approved by the National Ethical
Committee.
Results
The mean follow-up time after MIBG scintigraphy was
9.5 ± 1.28 months. The H/M ratio of the study group was
different in male and female individuals (men:
1.28 ± 0.11; women:1.60 ± 0.21, p = 0.008). The H/M
ratio decreased with age (p = 0.04) (Fig. 1). There was no
significantly lower H/M ratio in 13 patients taking anti-
hypertensive drugs, in comparison to those not taking such
medication (13 vs. 37, p = 0.3).
In setup A, 38 patients were analyzed and diagnostic
concordance was 64%. Thus, MD suggested IPD in a
further 28% of the patients, but this was not confirmed by
the clinical follow-up. In particular, patients with MSA
showed false positive scintigraphic results. Thus, seven
patients out of nine with MSA had an HM ratio below the
1.6 mark and 5 even below 1.4 (Table 1). In setup B, the
concordance rate was 88%. MD suggested LBD in a further
11%, but this was not confirmed by the clinical follow-up.
In setup C, MD suggested possible progression to PD/LBD
in both patients. Altogether, the concordance rate of MD
and CD was 68%. Table 2 shows sensitivity, specificity,
predictive positive value (PPV) and predictive negative
value (PNV) for the whole cohort.
Discussion
In contrast to other studies, the present study includes
patients with a wider range of diagnosis: patients with
different parkinsonian syndromes, different types of
dementia and idiopathic REM sleep behavior disorder
(IRBD). The resulting sensitivity of MIBG was in the
lower range of that in previous studies, whereas the spec-
ificity was low. Similarly, concordance rate found between
MD and CD was low, with discrepancy between both in
one-third of the patients. In particular, MD suggested more
cases of IPD than proven by CD [19]. The accuracy of
clinical diagnosis evidently increases with the duration of
the observation interval. However, the number of patients
was too small to determine if the frequency of false posi-
tive/false MIBG findings was affected by the duration of
the observation period.
According to literature [1, 6], MSA can be distinguished
from IPD by MIBG scintigraphy. However, we could not
confirm this observation. In particular, our results do not
uphold previous reports with almost normal MIBG uptake in
MSA patients. It is not excluded that one of our patients who
suffered from juvenile parkinsonism may not have MIBG-
sensitive parkinsonism with Lewy bodies. HMR decreased
with age and was higher in women than in men. False
positive results may be due to age-related, and not only IPD-
related postsynaptic noradrenergic degeneration. However,
since our control group was not age matched, an aging effect
was difficult to definitely assess. We ignored the reason for
different H/M uptake between men and women and this
issue should be further explored in a larger study. We could
refute the theoretical concern that antihypertensive drugs
may induce noradrenergic receptor desensitization and thus
reduce the HMR. We are aware of the debatable inadequacy
of our control group, which was obtained in a laboratory’s
control group who had an MIBG scintigraphy for
other reasons. We underline the fact that there was no other
available control group while performing our study.
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Considering the costs and especially the radiation exposure
of MIBG–SPECT, we were unable for ethical reasons to
recruit age-matched healthy controls, willing to undergo this
exam. Furthermore, the clinician defining the clinical
diagnosis was not blinded when evaluating the accuracy of
the MIBG–SPECT diagnosis. However, the diagnosis was
exclusively based on clinical grounds, following widely
accepted diagnostic criteria.
Table 1 Concordance (C) between MIBG diagnosis (MD) and final clinical diagnosis (CD) in 39 patients with parkinsonism. Concordance was
given in 25 patients (64%)
No Sex Age Indication H/M ratio MD CD C AHM OM CCM
24 w 64 IPD vs. NIP 2.4 N IPD NIP Y N – N
20 m 62 IPD vs. aP 2.4 N IPD MSA Y N – N
23 w 54 IPD vs. eT 2.3 N IPD eT Y N – N
37 w 82 IPD vs. aP 2.3 N IPD MSA Y N – N
4 w 50 IPD vs. NIP 2.1 N IPD NIP Y N – N
5 w 55 IPD vs. aP 2 N IPD PDS Y N – N
13 w 43 IPD vs. aP 2 N IPD PDS Y N Euthyrox TD TT
16 w 48 IPD vs. MSA 1.7 N IPD PDS Y N – N
50 m 47 IPD vs. aP 1.7 N IPD aP Y N Euthyrox TD TT
11 w 43 IPD vs. aP 1.6 N IPD PDS Y N N N
45 w 76 IPD vs. aP 1.6 N IPD PSP Y Y b-Blocker AHT TT
25 w 67 IPD vs. eT 1.6 IPD IPD Y Y ACE-Inhibitor, Euthyrox AHT TT, TD TT
30 w 79 IPD vs. MSA 1.5 IPD LBD Y N – –
47 w 72 IPD vs. MSA 1.2 IPD LBD Y N – N
43 m 59 IPD vs. MSA 1.2 IPD IPD Y N – N
10 m 75 IPD vs. aP 1.1 IPD IPD Y N – N
27 w 62 IPD vs. eT 1.1 IPD IPD Y N – –
3 m 73 IPD vs. aP 1.1 IPD IPD Y N – N
2 w 69 IPD vs. aP 1.1 IPD IPD Y Y Sartan, Euthyrox AHT, TD TT
8 w 73 IPD vs. MSA 1.1 IPD IPD Y Y Amiodarone Arrythmia
32 m 73 IPD vs. eT 1.1 IPD IPD Y N – N
36 m 60 IPD vs. eT 1.1 IPD IPD Y N Escitolopram N
17 m 87 IPD vs. eT 1.1 IPD IPD/LBD Y N – N
14 m 53 IPD vs. aP 1 IPD IDP Y Y ACE-Inhibitor AHT
44 m 60 IPD vs. MSA 1 IPD IPD Y N – N
18 w 75 IPD vs. aP 2.4 N IPD IPD N Y b-Blocker AHT
22 w 39 IPD vs. eT 1.9 N IPD IPD N N – N
38 m 41 IPD vs. MSA 1.8 N IPD IPD N N – N
40 w 76 IPD vs. aP 1.5 IPD MSA N N – N
9 w 77 IPD vs. aP 1.5 IPD PSP N Y b-Blocker AHT
28 m 54 IPD vs. MSA 1.4 IPD MSA N N – N
39 m 63 IPD vs. aP 1.4 IPD PSP N N Euthyrox TD TT
6 w 67 IPD vs. MSA 1.2 IPD MSA N N Euthyrox TD TT
48 m 74 IPD vs. MSA 1.1 IPD MSA N Y Sartan AHT
19 w 70 IPD vs. aP 1.1 IPD aP N N Olanzapine N
46 w 55 IPD vs. MSA 1.1 IPD MSA N N – N
41 m 73 IPD vs. MSA 1.1 IPD CBD N N – –
21 m 71 IPD vs. aP 1.1 IPD MSA N Y Sartan AHT
42 m 54 IPD vs. MSA 1 IPD MSA N N – N
No represents study n number of the patient
C Concordance, MD MIBG Scintigraphy diagnosis, CD clinical diagnosis, AHM antihypertensive medication, OM other medications, CCM
cardiac comorbidity, AP angina pectoris, TD TT thyroid dysfunction treated, IPD idiopathic Parkinson’s disease, MSA multiple system atrophy,
aP atypical parkinsonism, NIP neuroleptic induced parkinsonism, PSP progressive supranuclear palsy, eT essential tremor, PDS Parkinson
dystonia syndrome, CBD corticobasal degeneration, N No, Y Yes
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Although retrospective in nature and with only a small
number of control subjects who were not age matched, two
obvious limitations, our study has also notable strengths
including the rather large number of patients and clinical
diagnosis, based not only on a single cross-sectional
examination, but on several follow-up examinations.
Notably, in this series, patients on antihypertensive drugs
did not have significantly lower HMR. We were aware of
the fact that, presently, the complete withdrawal of these
medications is recommended [9, 17, 18]. In our opinion,
such a withdrawal is often impossible to realize in fragile
and multimorbid elderly patients. Furthermore, even with
accomplished withdrawal, there may be medication-
induced transitory or permanent postsynaptic noradrenergic
desensitization or, in contrast, secondary hypersensitiza-
tion. Future studies should readdress this issue and, ideally,
also recruit age-matched, healthy elderly control subjects,
despite the ethical concerns when applying a radioligand in
healthy volunteers. Instead of a unique cutoff value, age-
and gender-dependent cutoff values may increase the
diagnostic accuracy, although age dependency of the HMR
was not found by another group [20]. Standardization of the
methods (early HMR and/or late HMR) is also warranted.
Finally, cerebral dopamine transport-binding capacities
visualized by b-CIT–SPECT should be directly compared
with cardiac MIBG scintigraphy to achieve higher diag-
nostic accuracy. Presently, the results of MIBG scintigraphy
should be interpreted with caution in daily clinical practice.
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Fig. 1 Decreasing heart/mediastinum ratio (H/M ratio) of MIBG
scintigraphy in 50 patients with parkinsonism or dementia
Table 2 Diagnostic accuracy of the MIBG scintigraphy in terms of
sensitivity, specificity, predictive positive value (PPV) and predictive
negative value (PNV) in 50 patients with parkinsonism or dementia
95% CI (normal approximation)
Lower Upper
Sensitivity 87.5 74.2687 100.731
Specificity 46.1538 26.9918 65.316
PPV 60 43.77 76.23
PNV 80 59.7576 100.242
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